Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.…
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics (NASDAQ: MAZE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 141 employees.
The shares were at 31.37 USD on 20 November 2026, down 11.7% over 52 weeks. Its 52-week range is 21.95 USD to 53.65 USD: the price is 41.5% below the high and 42.9% above the low.
Its market capitalisation is 1.72B USD.
Maze Therapeutics reports return on equity of -36.9%.
It holds more cash than debt, a net cash position of 330.01M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 62.46 USD is 99.1% above the current price. The next earnings report is expected on 25 March 2027.